Asset profile
Adipose-derived MSC clusters (S.Biomedics)
Cell therapy
Evidence outlook · lead readout
NCT04661644 · Critical Limb Ischemia
The reported results come from study designs that frequently fail to replicate under controlled conditions; see the rationale below.
NCT04661644: The study was nonrandomized, open-label, and had no placebo or standard-treatment control arm; it enrolled 20 participants across sequential dose groups. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
68 competitors in this universe: 2 direct rivals (same mechanism and indication), 6 same-class, 60 same-indication; 64 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Adipose-Derived MSC Clusters (S.Biomedics): this drug | Phase 1/2 | Cell therapy | No discrete molecular target | ||
| ALF201 | Phase 2 | Cell therapy | No discrete molecular target | ||
| BGC101 | Phase 1/2 | Cell therapy | No discrete molecular target | ||
| Olvimulogene Nanivacirepvec | Phase 3 | Oncolytic Virus | No discrete molecular target | ||
| LN-145 | Phase 2 | Cell therapy | No discrete molecular target | ||
| RP1 | Phase 2 | Biologic (subtype unspecified) | No discrete molecular target | ||
| KB707 | Phase 1/2 | Gene therapy / editing | No discrete molecular target | ||
| SL-28 | Phase 1/2 | Biologic (subtype unspecified) | No discrete molecular target | ||
| KB-GDT-01 | Phase 1 | Biologic (subtype unspecified) | No discrete molecular target | ||
| Alirocumab (Praluent) | Approved | Monoclonal antibody | PCSK9 | ||
| Bempedoic Acid (Nexletol) | Approved | Small molecule | Adenosine Triphosphate-Citrate Lyase Inhibitor, ATP citrate lyase | ||
| Bempedoic Acid / Ezetimibe | Approved | Small molecule | ATP citrate lyase (ACLY, bempedoic acid) and NPC1L1 (ezetimibe) | ||
| Cangrelor (Kengreal) | Approved | Small molecule | P2Y12 receptor | ||
| Colchicine (cardiovascular) (Lodoco) | Approved | Small molecule | Microtubule/inflammasome (tubulin) | ||
| Dapagliflozin (Farxiga / Forxiga) | Approved | Small molecule | SGLT2 | ||
| Dulaglutide (Trulicity) | Approved | Peptide | GLP-1 receptor |
…and 53 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.